First Tracks Biotherapeutics Inc
TRAX | NASDAQ
$45.63
+$0.55 (+1.22%)
Nov 2, 2026, 9:49 AM ET · Market open
Company Profile
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Key Executives
| Name | Position |
|---|---|
| Daniel R. Faga | CEO, President & Director |
| Ajim A. Tamboli | Chief Financial Officer |
| Benjamin Stone | Chief Business Officer |
| Eric J. Loumeau | Secretary |
| Paul F. Lizzul | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 02, 2026 | 144 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | 424B3 | Filing |
First Tracks Biotherapeutics Inc
| Country | United States |
| IPO Date | Apr 20, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Daniel R. Faga |
Contact Details
10770 Wateridge Circle San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | TRAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002091349 |
| CUSIP Number | 337185102 |
| ISIN Number | US3371851029 |
| SIC Code | 2834 |
Recent News
- 18 days ago / globenewswire.comFirst Tracks Biotherapeutics Announces $200 Million Private Placement
- 19 days ago / seekingalpha.comFirst Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
- 21 days ago / marketbeat.comFirst Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals
- 21 days ago / benzinga.comFirst Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
- 22 days ago / globenewswire.comFirst Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
- 2 months ago / globenewswire.comFirst Tracks Biotherapeutics Announces Participation in September Investor Conferences
- 3 months ago / benzinga.comFirst Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
- 3 months ago / globenewswire.comFirst Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Add to Watchlist
Select watchlists to add or remove TRAX